Sanofi, a French healthcare business, announced on Wednesday that the first research into a high-dose influenza vaccination with a COVID-19 mRNA booster had yielded good results.
Sanofi stated initial findings from a trial comparing Sanofi’s Fluzone High-Dosage Quadrivalent vaccine to Moderna’s COVID-19 mRNA experimental booster dose revealed that the vaccines had similar immunogenicity responses as well as a similar safety and tolerability profile.
“These positive results could facilitate the implementation of Northern Hemisphere influenza and COVID-19 booster vaccination campaigns, especially in this high-risk population,” said Dr. Michael Greenberg, North America Medical Head for Vaccines at Sanofi.
Antibiotic use has surged globally, leading to a rise in antibiotic resistance, especially concerning in…
Choking is a leading cause of injury and death in young children, particularly those under…
Hard Water (Khara Pani) Leading To Hair Fall Hard water is rich in minerals and…
Discover how the rise in high blood pressure during pregnancy is impacting maternal and fetal…
"Discover the transformative power of six delicious homemade drinks that can help you naturally melt…
"Transform your weight loss routine with these eight delicious fat-flushing drinks that not only hydrate…